CCHT(000661)

Search documents
长春高新(000661) - 关于董事辞职的公告
2025-08-14 09:16
证券代码:000661 证券简称:长春高新 公告编号:2025-071 长春高新技术产业(集团)股份有限公司 关于董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 祝先潮先生在担任公司董事职务期间,勤勉尽责、恪尽职守,公司及董事会 对其为公司发展做出的贡献表示衷心的感谢! 特此公告 长春高新技术产业(集团)股份有限公司 董事会 2025年8月15日 长春高新技术产业(集团)股份有限公司(以下简称"公司")董事会于 近日收到公司董事祝先潮(英文名Jeff Xianchao Zhu)先生的书面辞职报告,基 于个人工作原因,祝先潮先生申请辞去公司第十一届董事会董事职务(原定任 期自2024年6月24日至2027年6月23日),辞职后将不再在公司及控股子公司担任 任何职务。 截至本公告披露日,祝先潮先生不存在应当履行而未履行的承诺事项,其持 有公司股份数量为3,200股,所持公司股份将严格按照《公司法》《证券法》《 上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等相关法律法 规的规定执行。根据《公司法》和《公司章程》的有关规定,其辞职申请自送 ...
今日237只个股突破五日均线
Zheng Quan Shi Bao Wang· 2025-08-12 03:13
Market Overview - The Shanghai Composite Index is at 3660.38 points, above the five-day moving average, with a change of 0.35% [1] - The total trading volume of A-shares is 858.514 billion yuan [1] Stocks Breaking the Five-Day Moving Average - A total of 237 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Yutian Guanjia (301173) with a deviation rate of 10.53% and a daily increase of 13.54% [2] - Meiri Hudong (300766) with a deviation rate of 8.80% and a daily increase of 11.81% [2] - Dayang Biological (003017) with a deviation rate of 8.02% and a daily increase of 10.00% [2] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Fenghuo Electronics (000561) with a deviation rate of 7.29% and a daily increase of 9.97% [2] - Shenzhou Taiyue (300002) with a deviation rate of 5.63% and a daily increase of 7.41% [2] - Lain Biological (002166) with a deviation rate of 5.26% and a daily increase of 6.70% [2] Summary of Stocks with Lower Deviation Rates - Stocks with smaller deviation rates that have just crossed the five-day moving average include: - Changchun Gaoxin, Lidasin, and Kaikai Industry [1]
长春高新子公司卡麦角林片临床试验申请获批
Zheng Quan Shi Bao Wang· 2025-08-11 13:33
Core Viewpoint - Changchun High-tech has received approval for clinical trials of its drug, Cabergoline Tablets, aimed at treating hyperprolactinemia and pituitary prolactin adenomas, marking a significant step in addressing unmet clinical needs in this area [1][2] Group 1: Product Development - Cabergoline Tablets are a dopamine receptor agonist with effective activity on dopamine D2 receptors, classified as a chemical drug of category 3, intended for the treatment of hyperprolactinemia and pituitary prolactin adenomas [1] - The drug has been approved for clinical trials in China, which will facilitate its clinical development and address unmet clinical needs for patients [2] - The original product of Cabergoline has been approved in over 80 countries since 1992, making it a first-line treatment for hyperprolactinemia and pituitary prolactin adenomas [2] Group 2: Market Context - Hyperprolactinemia is a common endocrine disorder, particularly among young women, with an annual incidence rate of 23.9 per 100,000 for women aged 25 to 34 [1] - The condition is prevalent in 10% to 25% of patients with secondary amenorrhea and 70% to 80% of patients with amenorrhea and galactorrhea, with 20% to 30% of hyperprolactinemia patients having pituitary tumors, primarily prolactinomas [1] Group 3: Company Strategy and Other Developments - Changchun High-tech is involved in various pharmaceutical sectors, including gene engineering, biological vaccines, antibody drugs, high-end chemical drugs, and modern traditional Chinese medicine [2] - The company has also received approvals for other products, including GenSci098 for thyroid eye disease and GenSci122 for advanced solid tumors, indicating a robust pipeline of clinical trials [3] - Additionally, the company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and financing capabilities [4]
长春高新(000661)8月11日主力资金净流出2693.83万元
Sou Hu Cai Jing· 2025-08-11 12:32
Group 1 - The core viewpoint of the news is that Changchun High-tech (000661) has experienced a decline in stock price and financial performance, indicating potential challenges for the company [1][3] - As of August 11, 2025, the stock closed at 104.44 yuan, down 0.49%, with a turnover rate of 1.47% and a trading volume of 58,600 lots, amounting to 609 million yuan [1] - The latest financial results for the first quarter of 2025 show total revenue of 2.997 billion yuan, a year-on-year decrease of 5.66%, and a net profit attributable to shareholders of 473 million yuan, down 44.95% year-on-year [1] Group 2 - The company has a current ratio of 4.323, a quick ratio of 2.956, and a debt-to-asset ratio of 16.20%, indicating a strong liquidity position [1] - Changchun High-tech has made investments in 26 companies and participated in 13 bidding projects, showcasing its active engagement in the market [2] - The company holds 30 trademark registrations and has obtained 6 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]
创新药械长牛,把握业绩、技术、需求要素,WCLC划重点
ZHONGTAI SECURITIES· 2025-08-11 11:14
Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2] Core Insights - The industry is entering an accelerated growth phase, driven by innovation in drug and medical device sectors, with a focus on performance, technology, and demand factors [4][11] - The market is experiencing differentiation, with a notable shift towards innovative drugs and medical devices, particularly in the context of AI-driven drug development and brain-computer interface technologies [4][8] - The report highlights the importance of selecting stocks based on robust performance, technological innovation, and potential for clinical research advancements [4][8] Summary by Sections Industry Investment Rating - The report rates the pharmaceutical and biotechnology industry as "Overweight" [2] Key Company Status - The report provides a detailed overview of key companies, including their stock prices, earnings per share (EPS) forecasts, and price-to-earnings (PE) ratios, with several companies rated as "Buy" [2] Market Trends - The report notes that the pharmaceutical sector has outperformed the broader market, with a year-to-date return of 21.28% compared to 4.32% for the CSI 300 index [13] - Recent market dynamics show a divergence within the pharmaceutical sector, with medical devices gaining traction while other segments like biopharmaceuticals and traditional medicine face declines [4][13] Investment Opportunities - The report suggests focusing on companies with stable or reversing performance, particularly in innovative drugs and medical devices, as well as those involved in AI-driven drug discovery [4][8] - Specific companies recommended for attention include WuXi Biologics, Innovent Biologics, and others involved in significant clinical research or technological advancements [4][8] Policy Support and Industry Growth - The report discusses the strong policy support for brain-computer interface technologies, which is expected to accelerate industry growth and innovation [11][9] - By 2027, key technological breakthroughs are anticipated, establishing a robust industry ecosystem with global competitiveness [11][9]
长春高新卡麦角林片临床试验申请获得批准
Bei Jing Shang Bao· 2025-08-11 09:48
Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial of its drug, Cabergoline Tablets, which is intended for the treatment of hyperprolactinemia and pituitary prolactin adenoma [1] Company Summary - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has been granted a clinical trial approval for Cabergoline Tablets, a dopamine receptor agonist [1] - The drug is classified as a Class 3 chemical drug and is aimed at treating conditions related to elevated prolactin levels [1] Industry Summary - The approval of Cabergoline Tablets indicates a positive development in the pharmaceutical industry, particularly in the area of treatments for hormonal disorders [1] - The drug's mechanism of action involves effective agonistic activity on the dopamine D2 receptor, which is crucial for its therapeutic application [1]
长春高新:控股子公司获得《药物临床试验批准通知书》
Mei Ri Jing Ji Xin Wen· 2025-08-11 09:36
长春高新(SZ 000661,收盘价:104.44元)8月11日晚间发布公告称,近日,长春高新技术产业(集 团)股份有限公司控股子公司——长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药 物临床试验批准通知书》,金赛药业卡麦角林片的境内生产药品注册临床试验申请获得批准。 2024年1至12月份,长春高新的营业收入构成为:制药业占比94.07%,房地产占比5.61%,服务业占比 0.32%。 (文章来源:每日经济新闻) ...
长春高新(000661) - 关于子公司卡麦角林片临床试验申请获得批准的公告
2025-08-11 09:30
证券代码:000661 证券简称:长春高新 公告编号:2025-070 长春高新技术产业(集团)股份有限公司 关于子公司卡麦角林片临床试验申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 近日,长春高新技术产业(集团)股份有限公司(以下简称"公司")控股 子公司——长春金赛药业有限责任公司(以下简称"金赛药业")收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》,金赛药业卡麦角林片的境 内生产药品注册临床试验申请获得批准,现将有关情况公告如下: 一、药品的基本情况 产品名称:卡麦角林片 卡麦角林片是金赛药业开发的一款多巴胺受体激动剂,对多巴胺 D2 受体具 有有效的激动剂活性,注册分类为化药 3 类,拟开发用于高催乳素血症/垂体催 乳素腺瘤的治疗。 高催乳素血症(hyperprolactinemia,HPRL)是由于各种原因引起外周血清催 乳素水平持续高于正常值的一种临床病理生理状态,由多种生理、药理、病理情 况引起。流行病学显示:高催乳素血症年轻女性常见的下丘脑-垂体轴内分泌紊 乱,25~34 岁妇女的年发病率为 23.9/10 ...
长春高新:长效生长激素持续领跑全球 10年15万例临床验证安全壁垒
Zheng Quan Shi Bao· 2025-08-06 14:49
Core Insights - Multiple long-acting growth hormones are nearing market approval, breaking the trend of only one product being launched in the past decade, which enhances the diversity of growth hormone options [1] - The safety, efficacy, and quality of new drugs, along with sufficient clinical feedback, are critical for competition in the market [1] Group 1: Product Development and Innovation - Long-term growth hormone technology involves modifying or protecting the hormone to extend its retention time in the body, addressing issues of short-acting formulations [2] - The core subsidiary of Changchun High-tech, Jinsai Pharmaceutical, has focused on developing domestic long-acting formulations after successfully launching short-acting growth hormones [2] - Jinsai Pharmaceutical has optimized the PEG modification process, achieving a half-life extension to 32 hours, allowing for weekly dosing and improved efficacy over short-acting formulations [2][3] Group 2: Quality and Safety Assurance - Ensuring efficacy and safety is paramount for long-acting growth hormones, with individual differences in pediatric patients necessitating long-term monitoring [4] - Jinsai Pharmaceutical has achieved a PEG purity of 100%, significantly higher than the typical 95% standard from suppliers, ensuring product quality and safety [6] - The company has invested heavily in developing a comprehensive production process to maintain high purity levels, overcoming challenges in production quality control [5][6] Group 3: Market Position and Future Strategy - Jinsai Pharmaceutical's long-acting growth hormone, Jinsai Zeng, is currently the only product approved for multiple indications, including GHD, ISS, and TS, setting it apart from competitors [7] - The company aims to expand its international presence and enhance patient care in the pediatric health sector, focusing on continuous improvement in drug formulation [7][8] - The establishment of a positive feedback loop between clinical breakthroughs and patient confidence is essential for driving further innovation in the growth hormone sector [8]
长春高新股价小幅下跌 公司拟赴港IPO引关注
Jin Rong Jie· 2025-08-04 19:21
Group 1 - The stock price of Changchun High-tech is reported at 104.78 yuan, down 0.86% from the previous trading day, with a trading volume of 7.74 billion yuan [1] - The company operates in the biopharmaceutical industry, focusing on the production and sales of biopharmaceuticals and traditional Chinese medicine, with a product line that includes growth hormones and vaccines [1] - Changchun High-tech announced its plan to pursue an IPO in Hong Kong in July, becoming one of 17 A-share companies to announce such plans that month [1] Group 2 - Recent clinical trials for a copy-type Tian Tan smallpox vaccine carrier HIV vaccine by the Chinese Center for Disease Control and Prevention may have a positive impact on the biopharmaceutical vaccine industry [1] - The net inflow of main funds into Changchun High-tech on the day was 471.66 million yuan, with a cumulative net inflow of 1.85 billion yuan over the past five days [1]